This promising new application for Remplir can potentially reduce post-surgical complications from peripheral nerve injury, representing a globally significant commercial opportunity for the Company.
Company to invest in further research to strengthen clinical evidence ahead of medium-term U.S. launch with no further FDA approvals needed PERTH, Australia, Nov. 20, 2025 /PRNewswire/ -- Orthocell ...
Learn about prostate cancer symptoms, diagnosis, staging and the latest treatments including robotic surgery, SBRT, radioligand therapy and targeted drugs.
PERTH, Australia, Nov. 20, 2025 /PRNewswire/ -- Orthocell Limited (ASX: OCC) is pleased to announce adoption of Remplir™ by Australian urologists is accelerating with the product increasingly being ...
This stock is getting a lot of attention from investors on Thursday. Orthocell's shares have risen following an update indicating increased adoption of its Remplir product by Australian urologists, ...
Investigators analyzed IBD subtypes and their associated risks of radical prostatectomy complications among a cohort of patients with prostate cancer to fill a knowledge gap.
Stage 3 prostate cancer is locally advanced, with tumors extending beyond the prostate but not metastasizing distantly.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results